New York Times, March 22, 2017
Reed Abelson

Links

Read the Full Article

[...] Insisting that he is not bluffing, Dr. Molina said that his company might also have to abandon the individual market after this year because so much is in flux. The Senate has yet to debate measures that could deeply affect insurers, and Molina Healthcare just reported to investors last month that it lost hundreds of millions of dollars in 2016 because of what Dr. Molina, its chief executive, called flawed federal funding formulas.

While the exit of other insurers has been problematic, a withdrawal by Molina “would be hugely damaging,” said Sabrina Corlette, a research professor at Georgetown University.

The reaction from other insurers has been muted, and the companies seem relieved that they are not being vilified in the way they were during the last debate over the Obama administration’s health care plan. This time, many seem eager to stay out of the fray. [...]

health care finance health care reform health law policy insurance market public health regulation